The present study showed that only IBTK and P4HA1 expressions were associated with the MSI status, suggesting that these two genes might contribute to the effect of oxaliplatin-based chemotherapy in CRC patients with different MSI statuses. This evidence concerns the gene IBTK and colorectal carcinoma.